Walmart is set to join the Nasdaq-100 Index, replacing British pharmaceutical giant AstraZeneca, as part of an index rebalancing effective before the market opens on January 20, according to a statement released by Nasdaq. This move follows Walmart’s earlier announcement in November that it would shift its primary stock listing from the New York Stock Exchange (NYSE) to Nasdaq, marking a significant change for the world’s largest retailer after decades on the NYSE.
The inclusion of Walmart in the Nasdaq-100 Index underscores the growing appeal of Nasdaq as a listing venue for large, high-profile companies. The Nasdaq-100 Index tracks 100 of the most valuable non-financial companies listed on the Nasdaq exchange and includes global leaders such as Apple, Nvidia, Microsoft, and Amazon. In addition to the main index, Walmart will also be added to the Nasdaq-100 Equal Weighted Index and the Nasdaq-100 Ex-Tech Sector Index, further expanding its presence across Nasdaq’s flagship benchmarks.
Companies often decide to change listing venues when they believe another exchange offers better alignment with their investor base, advanced trading technology, enhanced services, or lower listing and compliance costs. In recent years, Nasdaq has positioned itself as an attractive platform not only for technology companies but also for major consumer, healthcare, and industrial firms seeking broader exposure and index inclusion.
Several companies that moved from the NYSE to Nasdaq in 2025 cited the growing prestige and visibility of the Nasdaq-100 Index as a key factor in their decision. Being part of the index can lead to increased demand from index-tracking funds and institutional investors, potentially boosting liquidity and long-term shareholder value.
For Walmart, the transition represents more than a symbolic shift. It aligns the retail giant with a group of globally influential companies and reflects its evolving business model, which increasingly integrates e-commerce, technology, and data-driven operations. Meanwhile, AstraZeneca’s removal highlights the competitive and dynamic nature of major stock indices, where changes in market capitalization and listings can quickly reshape index composition.


SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business
Yaskawa Electric Shares Slide as Weak Profit Overshadows Strong AI Demand
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX
Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub
UBS Starts CarTrade Tech With Buy Rating, Sees Strong Earnings Growth and ₹4,000 Target
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO
Nvidia Tightens AI Chip Sales in Asia With Stricter Customer Approval Process
Australia Flags Child Safety Gaps at Apple, Meta, Google Over Online Sexual Extortion
SoftBank Corp Partners With Sierra to Expand AI Customer Support Across Japan
AstraZeneca Shares Sink After Wainua Trial Misses Key Heart Disease Goal
DOJ Grand Jury Investigates UAW President Shawn Fain Ahead of Union Election 



